Osteoid's Invivo and TX Studio Reaching End of Life Soon
End of Support Announcement for Invivo and TX Studio
Osteoid Inc. has made an important announcement regarding the future of its software offerings, specifically concerning Invivo and TX Studio version 6.5 and earlier. These older versions are set to officially reach their End of Life (EOL) on March 31, 2025. Users are encouraged to transition to the latest version, Invivo7, to ensure they receive updates, support, and security patches necessary for maintaining a high standard of operational excellence.
Importance of Upgrading
As part of the upgrade to Invivo7, users will gain access to cutting-edge features that enhance security measures and improve overall software performance. This transition is essential as it allows healthcare providers to utilize software that adheres to modern regulatory standards, ensuring patient data is protected.
Key Features of Invivo7 and TX Studio7
When upgrading to Invivo and TX Studio7, users will experience several significant improvements:
Simplified Licensing and More Control
The new versions offer streamlined licensing processes, making it easier for users to manage their software and ensuring they have maximum flexibility without unnecessary delays.
Improved Collaboration
With the introduction of Invivo Workspace, sharing patient cases becomes simpler, enabling better communication among colleagues and patients, resulting in improved treatment planning.
Enhanced Security Features
Security is a critical aspect of healthcare software. The latest updates include advanced features that significantly improve the protection of user and patient data against potential breaches.
Full Support and Continuous Updates
Upgrading also means that users will have access to ongoing technical support, ensuring that any questions or issues can be resolved quickly to minimize workflow disruptions.
Guidance for the Upgrade Process
For those considering the upgrade, Osteoid provides dedicated support to assist users through the process. Customers can reach out via phone or email to discuss their options and get help with any challenges.
Message from Calvin Hur, CEO of Osteoid
Calvin Hur, the CEO of Osteoid, emphasizes the positive aspects of transitioning to newer software versions. He acknowledges that while changes can be challenging, the advancements brought by Invivo7 will provide tremendous benefits in terms of efficiency and patient care.
About Osteoid Inc.
Osteoid Inc. has established itself as a leader in developing innovative diagnostic and treatment planning solutions. The company's commitment lies in empowering healthcare professionals with state-of-the-art tools and secure software, which are essential to operation in a fast-paced medical environment.
Frequently Asked Questions
What happens on March 31, 2025?
Invivo and TX Studio version 6.5 and earlier will no longer receive updates or support after this date.
Why should I upgrade to Invivo7?
Upgrading ensures access to the latest features, improved security, and continuous support, enhancing your practice's efficiency and patient safety.
How can I get help with the upgrade?
Osteoid provides support for users looking to upgrade. You can reach them via phone or email for assistance.
What are the benefits of Invivo7?
Benefits include simplified licensing, enhanced security, improved collaboration, and ongoing technical support for better practice management.
Who can I contact for further information?
You can contact Mike Joyce, Director of Sales at Osteoid, for detailed inquiries regarding the upgrade and support.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.